<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="35524">Sympathomimetic agents</z:chebi> have a poor history of long-term success in the treatment of <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>From earlier experiences with <z:chebi fb="110" ids="2679">amphetamine</z:chebi> and its analogs, to more recent drugs with direct effects on adrenergic receptors or indirect effects from release of <z:chebi fb="2" ids="33567">catecholamines</z:chebi> or inhibition of reuptake, cardiovascular toxicity (<z:hpo ids='HP_0001297'>strokes</z:hpo> and <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo>) has been the major concern </plain></SENT>
<SENT sid="2" pm="."><plain>These concerns also extended to food supplements containing ephedra <z:chebi fb="13" ids="22315">alkaloids</z:chebi> and may require consideration for current supplements containing the <z:chebi fb="0" ids="35524">sympathomimetic</z:chebi> drug, <z:chebi fb="0" ids="29081">synephrine</z:chebi> </plain></SENT>
</text></document>